Abivax S.A.
Status: Publicly traded
Direct answer
Abivax S.A. is publicly traded on PAR under the ticker ABVX.PA.
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This...
Can you invest in Abivax S.A.?
Yes. Abivax S.A. trades publicly on PAR as ABVX.PA.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Detailed equity research is provided by MarketSnap.